The notion that Hydroxychloroquine (HCQ) could be a safe, inexpensive, readily-available, and effective drug to mitigate the effect of SARS-CoV-1 provoked efforts to discredit and silence those who supported that hypothesis.
As the debate between HCQ and Remdesivir progressed, the potential benefits of HCQ were supported by credible scientists and medical organizations, forcing the NIH to test HCQ.
When Trump announced he'd been taking a regime of HCQ, it enhanced the tempo and temperature of the debate.
The likely end of Remdesivir considered as an effective treatment of patients with severe SARS-CoV-2 opened the way for a replacement drug to emerge from another lab.
The Lancet, a nearly 200-year old British medical journal, stated that no antiviral drug has yet been proven effective for patients with severe SARS-CoV-2.
Those pushing Remdesivir, until its wheels came off, either ignored or downplayed scholarly studies favorable to HCQ. And, in some cases, ridiculed those who took them seriously.
When pro-HCQ videos posted on YouTube, the site's Though Police deleted them and substituted the ominous dark screen above.
Review of Part 4 Takeaways
